-
公开(公告)号：US11780904B2
公开(公告)日：2023-10-10
申请号：US17086072
申请日：2020-10-30
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Leopold Grillberger , Manfred Reiter , Wolfgang Mundt
CPC classification number: C07K14/755 , A61K9/0019 , A61K38/36 , A61K38/37 , C12N9/6489 , C12P21/00 , A61K38/00 , C12N2500/24 , C12N2511/00 , C12Y304/24087
Abstract: Among other aspects, the present invention relates to cell culture conditions for producing high molecular weight vWF, in particular, highly multimericWF with a high specific activity and ADAMTS13 with a high specific activity. The cell culture conditions of the present invention can include, for example, a cell culture medium with an increased copper concentration and/or cell culture supernatant with a low ammonium (NH4+) concentration. The present invention also provides methods for cultivating cells in the cell culture conditions to express high molecular weight vWF and rA13 having high specific activities.
-
公开(公告)号：US20230242896A1
公开(公告)日：2023-08-03
申请号：US17927474
申请日：2021-05-25
Applicant: Sanquin IP B.V.
Inventor： Johannes Jacobus VOORBERG , Nuno Alexandre GOMES GRAÇA , Bogaç ERÇIG
CPC classification number: C12N9/6489 , C12Y304/24087 , A61P7/02
Abstract: The invention relates to ADAMTS13 protein variants comprising residues 1 to 685 of ADAMTS13 and wherein one or more N-linked glycosylation sites are added as compared to wild-type ADAMTS13 and/or one or more existing N-linked glycosylation sites are shifted as compared to wild-type ADAMTS13. The invention further relates to compositions comprising such ADAMTS13 variants, methods for their preparation and uses thereof, in particular as an antithrombotic agent, and in the treatment of thrombotic disease, thrombotic microangiopathy, thrombotic thrombocytopenic purpura (TTP), hemolytic—uremic syndrome (HUS), ischemic stroke, systemic thrombosis, COVID19, antiphospholipid syndrome, pre-eclampsia/HELLP syndrome, sepsis and sickle cell disease.
-
公开(公告)号：US09937244B2
公开(公告)日：2018-04-10
申请号：US15400526
申请日：2017-01-06
Applicant: BAXALTA INCORPORATED , BAXALTA GMBH
Inventor： Peter Matthiessen , Peter L. Turecek , Hans-Peter Schwarz
CPC classification number: A61K38/4886 , A61K9/0019 , A61K9/08 , A61K9/19 , A61K47/02 , A61K47/10 , A61K47/183 , A61K47/22 , A61K47/26 , C12Y304/24087
Abstract: The present invention relates to formulations of ADAMTS13 with enhanced or desirable properties. As such, the invention provides liquid and lyophilized formulations of ADAMTS13 that are suitable for pharmaceutical administration. Among other aspects, the present invention also provides methods of treating various diseases and conditions related to VWF and/or ADAMTS13 dysfunction in a subject. Also provided herein are kits comprising ADAMTS13 formulations useful for the treatment of various diseases and conditions.
-
公开(公告)号：US20170112906A1
公开(公告)日：2017-04-27
申请号：US15400526
申请日：2017-01-06
Applicant: BAXALTA INCORPORATED , BAXALTA GMBH
Inventor： Peter Matthiessen , Peter L. Turecek , Hans-Peter Schwarz
CPC classification number: A61K38/4886 , A61K9/0019 , A61K9/08 , A61K9/19 , A61K47/02 , A61K47/10 , A61K47/183 , A61K47/22 , A61K47/26 , C12Y304/24087
Abstract: The present invention relates to formulations of ADAMTS13 with enhanced or desirable properties. As such, the invention provides liquid and lyophilized formulations of ADAMTS13 that are suitable for pharmaceutical administration. Among other aspects, the present invention also provides methods of treating various diseases and conditions related to VWF and/or ADAMTS13 dysfunction in a subject. Also provided herein are kits comprising ADAMTS13 formulations useful for the treatment of various diseases and conditions.
-
公开(公告)号：US20160298121A1
公开(公告)日：2016-10-13
申请号：US14874420
申请日：2015-10-03
Applicant: Cold Spring Harbor Laboratory
Inventor： Adrian Krainer , Isabel Aznarez
IPC: C12N15/113 , C12Q1/68
CPC classification number: C12N15/1137 , C07K14/47 , C07K14/4702 , C07K14/4736 , C07K14/805 , C12N15/111 , C12N15/113 , C12N2310/11 , C12N2310/315 , C12N2310/3341 , C12N2320/11 , C12N2320/33 , C12Q1/6883 , C12Q2600/136 , C12Q2600/158 , C12Y101/01205 , C12Y304/24087 , C12N2310/321 , C12N2310/3521
Abstract: Provided herein are methods and compositions for increasing production of a target protein or functional RNA by a cell.
Abstract translation: 本文提供了用于增加细胞产生靶蛋白或功能性RNA的方法和组合物。
-
Patent Agency Ranking
公开(公告)号：US09351935B2
公开(公告)日：2016-05-31
申请号：US14088169
申请日：2013-11-22
Applicant: Baxter International Inc. , Baxter Healthcare S.A.
Inventor： Peter Matthiessen , Peter L. Turecek , Hans-Peter Schwarz
IPC: C12N9/00 , A61K38/00 , A61K9/19 , A61K9/08 , A61K38/48 , A61K47/02 , A61K47/10 , A61K47/18 , A61K47/26 , A61K9/00
CPC classification number: A61K38/4886 , A61K9/0019 , A61K9/08 , A61K9/19 , A61K47/02 , A61K47/10 , A61K47/183 , A61K47/22 , A61K47/26 , C12Y304/24087
Abstract: The present invention relates to formulations of ADAMTS13 with enhanced or desirable properties. As such, the invention provides liquid and lyophilized formulations of ADAMTS13 that are suitable for pharmaceutical administration. Among other aspects, the present invention also provides methods of treating various diseases and conditions related to VWF and/or ADAMTS13 dysfunction in a subject. Also provided herein are kits comprising ADAMTS13 formulations useful for the treatment of various diseases and conditions.
Abstract translation: 本发明涉及具有增强或期望性质的ADAMTS13制剂。 因此，本发明提供了适用于药物给药的ADAMTS13的液体和冻干制剂。 除了其它方面，本发明还提供了治疗受试者中与VWF和/或ADAMTS13功能障碍相关的各种疾病和病症的方法。 本文还提供了包含可用于治疗各种疾病和病症的ADAMTS13制剂的试剂盒。
-
公开(公告)号：US08906661B2
公开(公告)日：2014-12-09
申请号：US14166177
申请日：2014-01-28
Inventor： Kenji Soejima
CPC classification number: C12N9/6489 , A61K38/00 , A61K38/4886 , C12Y304/24087
Abstract: An enhanced disintegrin-like domain, and metalloprotease, with an isolated human thrombospondin type 1 motif, member 13 (ADAMTS-13) that includes substitutions at one or more positions in the isolated human ADAMTS-13.
Abstract translation: 具有分离的人类血小板反应蛋白1型基序的增强的解骨素样结构域和金属蛋白酶，成员13（ADAMTS-13），其包括在分离的人ADAMTS-13中的一个或多个位置的取代。
-
公开(公告)号：US20140271611A1
公开(公告)日：2014-09-18
申请号：US14210167
申请日：2014-03-13
Applicant: BAXTER HEALTHCARE SA , BAXTER INTERNATIONAL INC.
Inventor： Alexandra Nathalie Schiviz , Werner Höllriegl , Barbara Plaimauer , Hanspeter Rottensteiner , Eva-Maria Muchitsch
IPC: C12N9/64
CPC classification number: A61K38/4886 , A61K9/0019 , A61K9/19 , C12N9/6489 , C12Y304/24087
Abstract: This invention relates to methods of subcutaneous administration of ADAMTS13 formulations to a treat a disease or condition associated with ADAMTS13 and VWF dysfunction. Furthermore, evidence of the unexpectedly high bioavailability of ADAMTS13 formulations administered subcutaneously is provided herein.
Abstract translation: 本发明涉及皮下给药ADAMTS13制剂以治疗与ADAMTS13和VWF功能障碍相关的疾病或病症的方法。 此外，本文提供了皮下给药的ADAMTS13制剂意想不到的高生物利用度的证据。
-
9.发明申请Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV 有权表现出von Willebrand因子（vWF）蛋白酶活性的组合物，其包含具有氨基酸序列AAGGILHLELLV的多肽链公开(公告)号：US20020136713A1
公开(公告)日：2002-09-26
申请号：US09833328
申请日：2001-04-12
Inventor： Bernhard Laemmle , Helena Elisabeth Gerritsen , Miha Furlan , Peter Turecek , Hans-Peter Schwarz , Friedrich Scheiflinger , Gerhard Antoine , Randolf Kerschbaumer , Luigina Tagliavacca , Klaus Zimmermann
IPC: A61K038/48 , C12N009/64
CPC classification number: A61K38/4886 , A61K38/00 , C07K14/755 , C07K16/36 , C12N9/6416 , C12N9/6489 , C12Y304/24087
Abstract: The invention relates to vWF cleaving entities having a molecular weight of 180 kD, 170 kD, 160 kD, 120 kD or 110 kD and an N-terminal amino acid sequence of AAGGILHLELLV, vWF cleaving complexes and methods for their production.
Abstract translation: 本发明涉及分子量为180kD，170kD，160kD，120kD或110kD的VWF切割实体以及AAGGILHLELLV的N-末端氨基酸序列，vWF切割复合物及其生产方法。
-
公开(公告)号：US20230295597A1
公开(公告)日：2023-09-21
申请号：US18041493
申请日：2021-08-12
Inventor： Abd Alrauf HIJAZI , Suhair Abd Eljawad ABDEEN
CPC classification number: C12N9/6489 , C07K14/46 , A61K38/1703 , C12Y304/24087 , A61K38/4886 , C12Y304/24068 , A61K38/36 , A61P7/02 , C07K2319/35
Abstract: The present invention relates to ADAMTS-13 mutants and/or variant/s that display resistance to tPA cleavage and/or inactivation. The present disclosure further provides fibrinolytic compounds, compositions, combined compositions and kits comprising the ADAMTS-13 mutants disclosed herein, as well as uses thereof for treating coagulation related disorders.
-
-
-
-
-
-
-
-
-
Search Results
75
records
(took 0.034 seconds)
